REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification
REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification
Active, not recruiting · NCT01252953 · Registry updated 2024-06-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, vascular disorder | Active, not recruiting | Phase 3 | 2024-06-25 | NCT01252953 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Merck Sharp & Dohme LLC | 650 |
| University of Oxford | 213 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| CTSU, University of Oxford | Oxford | United Kingdom | 2 |